
-
Zuckerberg repeats Trump visits in bid to settle antitrust case
-
US fencer disqualified for not facing transgender rival
-
'Everyone worried' by Trump tariffs in France's champagne region
-
Italy's Brignone suffers broken leg with Winter Olympics looming
-
Iyer blitz powers Kolkata to big IPL win over Hyderabad
-
Russian soprano Netrebko to return to London's Royal Opera House
-
French creche worker gets 25 years for killing baby with drain cleaner
-
UK avoids worst US tariffs post-Brexit, but no celebrations
-
Canada imposing 25% tariff on some US auto imports
-
Ruud wants 'fair share' of Grand Slam revenue for players
-
Lesotho, Africa's 'kingdom in the sky' jolted by Trump
-
Trump's trade math baffles economists
-
Gaza heritage and destruction on display in Paris
-
'Unprecedented crisis' in Africa healthcare: report
-
Pogacar gunning for blood and thunder in Tour of Flanders
-
Macron calls for suspension of investment in US until tariffs clarified
-
Wall St leads rout as world reels from Trump tariffs
-
Mullins gets perfect National boost with remarkable four-timer
-
Trump tariffs hammer global stocks, dollar and oil
-
Authors hold London protest against Meta for 'stealing' work to train AI
-
Tate Modern gifted 'extraordinary' work by US artist Joan Mitchell
-
Mexico president welcomes being left off Trump's new tariffs list
-
Tonali eager to lead Newcastle back into Champions League
-
Lesotho hardest hit as new US tariffs rattle Africa
-
Stellantis pausing some Canada, Mexico production over Trump auto tariffs
-
Rising odds asteroid that briefly threatened Earth will hit Moon
-
Italy reels from Brignone broken leg with Winter Olympics looming
-
Is the Switch 2 worth the price? Reviews are mixed
-
Ancelotti’s tax trial wraps up in Spain with prosecutors seeking jail
-
Civilians act to bring aid to Myanmar earthquake victims
-
US trade gap narrows in February ahead of bulk of Trump tariffs
-
Stocks, dollar and oil sink as gold hits high on Trump tariffs
-
Countries eye trade talks as Trump tariff blitz roils markets
-
Arsenal defender Gabriel out for rest of the season
-
Trump says US to emerge 'stronger' as markets tumble over tariffs
-
Wiegman says Belgium games can aid England's women's Euros title defence
-
Prosecutors demand jail term for Ancelotti for tax fraud
-
Syria accuses Israel of deadly destabilisation campaign
-
Skiing World Cup champion Brignone suffers broken leg
-
Iconic Paris hotel Lutetia taken over by Mandarin Oriental
-
Nepal capital chokes as wildfires rage
-
AI could impact 40 percent of jobs worldwide: UN
-
'Shocking': US tariffs worse than feared for Vietnamese exporters
-
Liverpool's Slot happy to let Premier League title bid take its course
-
USA sole bidder for 2031 Women's World Cup, UK set to host in 2035
-
Tesla sales fall again in Germany amid Musk backlash
-
Italy's skiing champion Brignone air-lifted to hospital after crash
-
US trade partners eye talks after Trump tariff blitz
-
Evenepoel adds Tour de Romandie to comeback programme
-
Defending champion I Am Maximus heads final field for Grand National
RYCEF | 0.2% | 9.8 | $ | |
RBGPF | -0.41% | 67.72 | $ | |
SCS | -5.62% | 10.85 | $ | |
RIO | -1.93% | 58.765 | $ | |
CMSC | -0.94% | 22.29 | $ | |
GSK | 3.62% | 39.055 | $ | |
BTI | 4.27% | 42.045 | $ | |
AZN | 2.74% | 74.255 | $ | |
RELX | 1.23% | 51.615 | $ | |
NGG | 5.26% | 69.43 | $ | |
VOD | 2.67% | 9.37 | $ | |
BCE | 2.63% | 22.41 | $ | |
JRI | -1.56% | 12.84 | $ | |
BP | -7.28% | 31.515 | $ | |
BCC | -7.62% | 94.84 | $ | |
CMSD | -0.73% | 22.665 | $ |

Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
O.Lorenz--BTB